



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	Recombinant human PARP7 (Poly [ADP-ribose] polymerase 7, also known as TIPARP), encompassing amino acids 400-657(end). This construct contains an N-terminal FLAG-tag. This recombinant protein was affinity purified.
<b>Background:</b>	PARP7, also known as poly-(ADP-ribose) polymerase 7 or NAD <sup>+</sup> ADP-ribosyltransferase 7, is part of the PARP family. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Mono-ADP-ribosylation (termed MARylation) is the addition of a unit of ADP-ribose. PARP7 is a negative regulator of nucleic acid sensing in cancer cells. Tumor cells contain cytosolic DNA as a reflection of defects in DNA repair and must repress responses coming from the adaptative immune system. PARP7 is an AHR (aryl hydrocarbon receptor) regulated gene that inhibits STING (stimulator of interferon genes) and IFN-I (interferon type I). RBN-2397 is a pyridazinone-based PARP7 inhibitor that results in STING-dependent and IFN-I activation and leads to cancer cell death <i>in vitro</i> and it is currently under clinical trial. The development of PARP7 inhibitors is thus a promising area in cancer research.
<b>Species:</b>	Human
<b>Construct:</b>	PARP7 (Flag-400-657(end))
<b>Concentration:</b>	0.32 mg/ml
<b>Expression System:</b>	Sf9
<b>Purity:</b>	70%
<b>Format:</b>	Aqueous buffer solution.
<b>Formulated In:</b>	50 mM Tris, pH 8.0, 150 mM NaCl, 0.8 M Arginine, and 10% glycerol
<b>MW:</b>	31 kDa
<b>Genbank Accession:</b>	NM_015508
<b>Stability:</b>	At least 6 months at -80°C.
<b>Storage:</b>	-80°C
<b>Instructions for Use:</b>	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
<b>Assay Conditions:</b>	Assay was performed according to the PARP7 Chemiluminescent Assay Kit (BPS Bioscience #79729-1).
<b>Applications:</b>	Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

## Quality Control Data

### 4-20% SDS-PAGE Coomassie Staining



### PARP7 Activity

